Safety and efficacy of entecavir in adefovir‐experienced patients

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Gastroenterology and Hepatology

• Publication date

  2015-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jgh.12728PMID 25168842
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural history of chronic hepatitis B virus infection

  2014cited by this paper
• Resolution of adefovir‐related nephrotoxicity by adefovir dose‐reduction in patients with chronic hepatitis B

  2013cited by this paper
• Hepatitis B viral factors and treatment responses in chronic hepatitis B.

  2013cited by this paper
• Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg‐positive chronic hepatitis B patients with resistance to adefovir dipivoxil

  2013cited by this paper
• Renal tubular dysfunction during long‐term adefovir or tenofovir therapy in chronic hepatitis B

  2012cited by this paper
• Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective

  2012cited by this paper
• Frequency and risk factors of renal impairment during long‐term adefovir dipivoxil treatment in chronic hepatitis B patients

  2012cited by this paper
• Review article: current antiviral therapy of chronic hepatitis B

  2011cited by this paper
• The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir

  2011cited by this paper
• Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.

  2010cited by this paper
• Chronic hepatitis B : an update

  2010cited by this paper
• Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines.

  2010cited by this paper
• Chronic hepatitis B: Update 2009

  2009cited by this paper
• Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

  2009cited by this paper
• Hepatitis B virus DNA levels and outcomes in chronic hepatitis B

  2009cited by this paper
• Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil

  2009cited by this paper
• The natural history of chronic hepatitis B virus infection

  2009cited by this paper
• Chronic hepatitis B: early viral suppression and long‐term outcomes of therapy with oral nucleos(t)ides

  2009cited by this paper
• Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.

  2009cited by this paper
• A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.

  2008cited by this paper
• Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

  2008cited by this paper
• Review article: current antiviral therapy of chronic hepatitis B

  2008cited by this paper
• Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.

  2008cited by this paper
• Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

  2007cited by this paper
• Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BLai C-L, for the BEHoLD AI463027 Study Group (Queen Mary Hosp, Hong Kong; et al) N Engl J Med 354:1011–1020, 2006§

  2007cited by this paper
• A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

  2007cited by this paper
• Long-term outcomes in hepatitis B: the REVEAL-HBV study.

  2007cited by this paper
• In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents

  2006cited by this paper
• Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

  2006cited by this paper
• Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

  2006cited by this paper
• A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

  2006cited by this paper
• A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.

  2006cited by this paper
• Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

  2005cited by this paper
• Epidemiology of hepatocellular carcinoma.

  2005cited by this paper
• Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir

  2005cited by this paper
• Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

  2005cited by this paper
• Epidemiology and Natural History of Hepatitis B

  2005cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China

  2005cited by this paper
• Emerging treatments in chronic hepatitis B

  2004cited by this paper
• Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

  2003cited by this paper
• Chronic hepatitis B

  2001cited by this paper
• [Chronic hepatitis B].

  2001cited by this paper
• Chronic hepatitis B.

  2001cited by this paper
• Epidemiology of hepatocellular carcinoma.

  1995cited by this paper

• Present and Future Therapies for Chronic Hepatitis B.

  2020cites this paper
• Taiwan consensus statement on the management of chronic hepatitis B.

  2019cites this paper
• Hepatitis B Virus Drug Resistance

  2017cites this paper
• A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients

  2016cites this paper
• An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults

  2016cites this paper
• A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.

  2015cites this paper
• Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients

  2015cites this paper